Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$86.79

-0.8599 (-0.98%)

13:10
10/06/17
10/06
13:10
10/06/17
13:10

Eli Lilly announces data from MONARCH 3 study of Verzenio

Eli Lilly and Company announced that interim results from the double-blind, placebo-controlled Phase 3 MONARCH 3 study evaluating Verzenio, a cyclin-dependent kinase 4 & 6 inhibitor, in combination with a nonsteroidal aromatase inhibitor were published online in the Journal of Clinical Oncology. These data, presented at the European Society for Medical Oncology 2017 Congress in September, demonstrated that abemaciclib plus an NSAI resulted in a statistically significant improvement in progression-free survival and objective response rate compared to an NSAI alone in women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. MONARCH 3 met a rigorous threshold for demonstrating efficacy at the time of pre-planned interim analysis with a 46% reduction in the risk of progression or death in patients receiving initial therapy for metastatic disease. The median PFS for abemaciclib in combination with an NSAI was not reached, compared to 14.7 months in the placebo arm. These results are supported by an improvement in response rate, with a 59.2% ORR in patients with measurable disease, including five patients achieving a complete response. Median duration of response was not reached in the abemaciclib-plus-NSAI arm. Final PFS results are expected at the end of the year and will be presented at a scientific congress in 1H18. In MONARCH 3, abemaciclib in combination with an NSAI was generally well tolerated. The most frequent adverse events of any grade in the abemaciclib-plus-NSAI arm were diarrhea, neutropenia, fatigue, infections, and nausea. Of these, the reported Grade 3/4 AEs in the abemaciclib-plus-NSAI arm versus the placebo-plus-NSAI arm were diarrhea, neutropenia, fatigue, infections, and nausea. Severity and frequency of diarrhea generally decreased following 28 days, and was managed with over-the-counter antidiarrheal medication and dose adjustment. The majority of patients in the abemaciclib-plus-NSAI arm with an AE of diarrhea did not require treatment modification and 2.3% of patients discontinued treatment with abemaciclib due to diarrhea

  • 18

    Oct

  • 24

    Oct

  • 06

    Nov

LLY Eli Lilly
$86.79

-0.8599 (-0.98%)

09/18/17
LEER
09/18/17
NO CHANGE
Target $107
LEER
Outperform
Clovis rumors 'unsubstantiated,' but company could be M&A target, says Leerink
Leerink analyst Michael Schmidt noted Bloomberg highlighted speculation claiming that Eli Lilly (LLY) had submitted a $110 per share offer to acquire Clovis (CLVS). While he views the speculation as "unsubstantiated" and the social media sources attributed as "highly questionable," he does think Clovis could be a possible takeout candidate and he does believe the addition of a PARP inhibitor makes a lot of strategic sense for Lilly. He reiterates an Outperform rating and $107 price target on Clovis shares, which are up 9% to $75.91 in afternoon trading.
09/29/17
MSCO
09/29/17
NO CHANGE
Target $86
MSCO
Equal Weight
Morgan Stanley calls Verzenio liver toxicity warning a 'minor' negative surprise
Morgan Stanley analyst David Risinger said he was expecting warnings on diarrhea and blood clot risks for Eli Lilly's (LLY) Verzenio, but not liver toxicity, calling that part of the approval a "minor" negative surprise. However, the approval came ahead of the Q1 timeline management had provided, he added. Bloomberg reports that Verzenio will cost $10,948 per month, which is in-line with the current monthly costs for Pfizer's (PFE) Ibrance and Novartis' (NVS) Kisqali, Risinger noted. He keeps an Equal Weight rating and $86 price target on Eli Lilly shares.
10/05/17
GSCO
10/05/17
NO CHANGE
Target $95
GSCO
Buy
Eli Lilly price target raised to $95 after Alimta patent upheld at Goldman Sachs
Goldman Sachs analyst Jami Rubin noted that the USPTO upheld the validity of all 22 claims on Eli Lilly's method of use patent for Alimta, which he believes restores confidence in the lung cancer drug's durability through its patent expiry in May 2022. Rubin raise his price target on Eli Lilly shares to $95 from $92 and keeps a Buy rating on the stock.
10/06/17
MSCO
10/06/17
NO CHANGE
Target $86
MSCO
Equal Weight
Eli Lilly Alimta patent decision was already assumed, says Morgan Stanley
Morgan Stanley analyst David Risinger said the USPTO final decision upholding Alimta's '209 patent removes an overhang for Eli Lilly, but he also contends that the consensus view was assuming the patent would be upheld. He maintains his Alimta sales estimates and keeps an Equal Weight rating and $86 price target on Eli Lilly shares.

TODAY'S FREE FLY STORIES

03:05
10/19/17
10/19
03:05
10/19/17
03:05
General news
FX Update: The yen continued to underperform »

FX Update: The yen…

MERC

Mercer

$13.50

-0.05 (-0.37%)

20:51
10/18/17
10/18
20:51
10/18/17
20:51
Upgrade
Mercer rating change at RBC Capital »

Mercer upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

ADBE

Adobe

$153.00

2.62 (1.74%)

20:50
10/18/17
10/18
20:50
10/18/17
20:50
Upgrade
Adobe rating change at Pivotal Research »

Adobe upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 06

    Nov

MDB

MongoDB

20:46
10/18/17
10/18
20:46
10/18/17
20:46
Syndicate
MongoDB 8M share IPO priced at $24.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

VZ

Verizon

$48.65

0.25 (0.52%)

, PM

Philip Morris

$112.51

-0.14 (-0.12%)

20:25
10/18/17
10/18
20:25
10/18/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

VZ

Verizon

$48.65

0.25 (0.52%)

PM

Philip Morris

$112.51

-0.14 (-0.12%)

DHR

Danaher

$86.05

0.79 (0.93%)

BK

BNY Mellon

$54.46

0.5 (0.93%)

BX

Blackstone

$33.49

0.27 (0.81%)

BBT

BB&T

$46.54

0.02 (0.04%)

TRV

Travelers

$130.02

1.37 (1.06%)

PPG

PPG

$112.88

-0.08 (-0.07%)

RCI

Rogers Communications

$53.75

-0.23 (-0.43%)

NUE

Nucor

$57.28

0.17 (0.30%)

DOV

Dover

$93.57

-0.48 (-0.51%)

GPC

Genuine Parts

$98.04

1.18 (1.22%)

TXT

Textron

$53.57

0.5 (0.94%)

DGX

Quest Diagnostics

$92.05

-0.13 (-0.14%)

ADS

Alliance Data

$228.38

1.44 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 30

    Oct

  • 01

    Nov

  • 06

    Nov

  • 07

    Nov

  • 13

    Nov

  • 16

    Nov

  • 29

    Nov

  • 30

    Nov

  • 14

    Dec

HPE

HP Enterprise

$14.70

0.09 (0.62%)

19:12
10/18/17
10/18
19:12
10/18/17
19:12
Hot Stocks
HP Enterprise raises share buyback by $5B, raises regular dividend 15% »

Given HPE's strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 11

    Dec

HPE

HP Enterprise

$14.70

0.09 (0.62%)

19:11
10/18/17
10/18
19:11
10/18/17
19:11
Hot Stocks
HPE to simplify organizational structure, to drive cost savings of $1.5B »

HPE President Antonio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 11

    Dec

HPE

HP Enterprise

$14.70

0.09 (0.62%)

19:10
10/18/17
10/18
19:10
10/18/17
19:10
Earnings
HP Enterprise sees FY17 adjusted EPS view roughly $1.00, consensus $1.40 »

Sees FY17 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 11

    Dec

HPE

HP Enterprise

$14.70

0.09 (0.62%)

19:08
10/18/17
10/18
19:08
10/18/17
19:08
Earnings
HP Enterprise sees FY18 adjusted EPS $1.15-$1.25, consensus $1.20 »

HPE expects its non-GAAP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 11

    Dec

CME

CME Group

$136.37

0.18 (0.13%)

19:01
10/18/17
10/18
19:01
10/18/17
19:01
Hot Stocks
CME Group, JPX enter agremenet to launch TOPIX futures contract on CME »

CME Group and Japan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 26

    Oct

  • 07

    Nov

UAL

United Continental

$67.99

0.48 (0.71%)

18:50
10/18/17
10/18
18:50
10/18/17
18:50
Hot Stocks
Breaking Hot Stocks news story on United Continental »

United Continental sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

CSX

CSX

$53.68

-0.55 (-1.01%)

18:49
10/18/17
10/18
18:49
10/18/17
18:49
Hot Stocks
CSX discloses reduction of locomotives in maintenance program »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 30

    Oct

VZ

Verizon

$48.65

0.25 (0.52%)

18:41
10/18/17
10/18
18:41
10/18/17
18:41
Periodicals
Verizon targets spring 2018 start of delayed online TV service, Bloomberg says »

Verizon is targeting a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

IBM

IBM

$159.53

12.99 (8.86%)

18:37
10/18/17
10/18
18:37
10/18/17
18:37
Hot Stocks
IBM CFO: Great start to 2H17 »

Says dollar is important…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 15

    Nov

SEAS

SeaWorld

$12.31

-0.17 (-1.36%)

18:26
10/18/17
10/18
18:26
10/18/17
18:26
Hot Stocks
SeaWorld to eliminate approximately 350 positions in restructuring program »

On October 18, SeaWorld…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

JPM

JPMorgan

$97.99

0.37 (0.38%)

18:12
10/18/17
10/18
18:12
10/18/17
18:12
Hot Stocks
SEC names JPMorgan exec Redfearn Director of Division of Trading and Markets »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

  • 22

    Oct

  • 23

    Oct

  • 02

    Nov

  • 05

    Nov

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

VZ

Verizon

$48.65

0.25 (0.52%)

18:10
10/18/17
10/18
18:10
10/18/17
18:10
Periodicals
Verizon targets spring start of delayed online TV service, Bloomberg says »

Verizon web TV…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

STLD

Steel Dynamics

$36.44

0.27 (0.75%)

18:04
10/18/17
10/18
18:04
10/18/17
18:04
Hot Stocks
Steel Dynamics CEO optimistic conditions in place to benefit FY18 consumption »

CEO Mark Millet said:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

CE

Celanese

$104.03

-0.24 (-0.23%)

18:03
10/18/17
10/18
18:03
10/18/17
18:03
Earnings
Celanese increases price for acetyls and engineered materials products »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLD

Steel Dynamics

$36.44

0.27 (0.75%)

18:01
10/18/17
10/18
18:01
10/18/17
18:01
Earnings
Steel Dynamics reports Q3 ex-items EPS 66c, consensus 66c »

Reports Q3 revenue $2.4B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

OPTT

Ocean Power

$2.00

0.56 (38.89%)

17:59
10/18/17
10/18
17:59
10/18/17
17:59
Syndicate
Ocean Power files to sell common stock in 'best efforts' offering »

No amount was provided.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

TOSBF

Toshiba, also use TOSYY

$3.02

-0.03 (-0.98%)

, TOSYY

Toshiba, also use TOSBF

$18.20

-0.11 (-0.60%)

17:58
10/18/17
10/18
17:58
10/18/17
17:58
Periodicals
Japan regulators probing Toshiba reporting practices for FY16/17, Nikkei says »

Japan's Securities…

TOSBF

Toshiba, also use TOSYY

$3.02

-0.03 (-0.98%)

TOSYY

Toshiba, also use TOSBF

$18.20

-0.11 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNW

Pinnacle West

$87.34

-0.42 (-0.48%)

17:53
10/18/17
10/18
17:53
10/18/17
17:53
Hot Stocks
Pinnacle West raises quarterly divided 6.1% to 69.5c per share »

Pinnacle West…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

GILD

Gilead

$80.01

-0.23 (-0.29%)

17:46
10/18/17
10/18
17:46
10/18/17
17:46
Hot Stocks
FDA grants regulatory approval to Kite's Yescarta »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 26

    Oct

  • 06

    Nov

  • 12

    Feb

POT

Potash

$19.24

0.08 (0.42%)

, AGU

Agrium

$107.73

0.55 (0.51%)

17:37
10/18/17
10/18
17:37
10/18/17
17:37
Hot Stocks
Potash, Agrium: India approves proposed merger of equals transaction »

Potash Corporation of…

POT

Potash

$19.24

0.08 (0.42%)

AGU

Agrium

$107.73

0.55 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.